U.S. markets open in 9 hours 11 minutes

Voyageur Pharmaceuticals Ltd. (VM.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.04500.0000 (0.00%)
At close: 1:13PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0450
Open0.0450
Bid0.0450 x 0
Ask0.0500 x 0
Day's Range0.0450 - 0.0450
52 Week Range0.0450 - 0.1200
Volume30,000
Avg. Volume58,263
Market Cap3.211M
Beta (5Y Monthly)1.30
PE Ratio (TTM)N/A
EPS (TTM)-0.0160
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Read This Before Selling Voyageur Pharmaceuticals Ltd. (CVE:VM) Shares
      Simply Wall St.

      Read This Before Selling Voyageur Pharmaceuticals Ltd. (CVE:VM) Shares

      We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

    • GlobeNewswire

      Voyageur Secures Exclusive Rights To One Of The Worlds Rarest Pharmaceutical Minerals, Creating A New Era In Carbon Based Drug Development

      Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (VYYRF) (the “Company” or “Voyageur”) is pleased to announce it has signed an LOI with an established international mining company (the “Counterparty”) that has developed a low cost method to extract the natural occurring carbon molecule, C-60 to C-90, from  large natural-occurring fullerene resources. “Voyageur will be the first company to be able to mass produce C-60 at a low cost, allowing for multiple drug products to be developed,” states Brent Willis, CEO of Voyageur Pharmaceuticals. “The barriers for C-60 based drugs has now been broken, which opens up the industry to develop new effective drugs and health care products on an economic scale,” continues Brent Willis.

    • GlobeNewswire

      Voyageur Restructures its ImagingX Joint Venture

      Voyageur Pharmaceuticals Ltd. (VM.V) (the “Company” or “Voyageur”) is pleased to announce the dissolution of the current joint venture with Chief Medical Supplies (“Chief”). Voyageur and Chief have worked together to create a new working relationship that is more beneficial to both parties. Voyageur will move the projects forward using manufacturing agreements in place of the joint venture structure.